Extended antidepressant maintenance and discontinuation syndromes

Depression and Anxiety

Volumn 8, Issue SUPPL. 1, 1998, Pages 43-53

  Maixner, Susan M ^a   Greden, John F ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Antidepressant; Compliance; Discontinuation; Drug therapy; Long term treatment; Maintenance; SSRI; Tricyclic antidepressant; Withdrawal

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; DIMENHYDRINATE; FLUOXETINE; HETEROCYCLIC COMPOUND; LITHIUM; MECLOZINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ZIMELDINE;

ARTICLE; CLINICAL FEATURE; DEPRESSION; DOSE RESPONSE; DRUG TOLERANCE; GAIT DISORDER; HUMAN; LONG TERM CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT DISEASE; VERTIGO; WITHDRAWAL SYNDROME;

EID: 0031758535     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1520-6394(1998)8:1+<43::aid-da7>3.0.co;2-c     Document Type: Article

References (121)

1. Altamura AC, Pcrcudani M (1993) The use of antidepressants for long-term treatment of recurrent depression: Rationale, current methodologies and future directions. J Clin Psychiatry 54:29-37.
2. Amsden GW, Georgian F (1996) Orthostatic hypotension induced by sertraline withdrawal. Pharmacotherapy 16:684-686.
3. Andersen H, Kristiansen ES (1959) Tofranil-treatment of endogenous depressions. Acta Psychiatr Scand 34:387-397.
4. Anderson LM, Tomenson BM (1995) Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis. BMJ 310:1433-1438.
5. Angst J, Baastrup P, Grof P, Hippius H, Poldinger W, Weis P (1973) The course of monopolar depression and bipolar psychoses. Psychiat Neurol Neurochir 76:489-500.
6. Anon (1993) Dystonia and withdrawal symptoms with paroxetine (Seroxat). Current Problems in Pharmacovigilance 19:1.
7. Anton SF, Robinson DS, Roberts DZ (1994) Long-term treatment of depression with nefazodone. Psychopharmacol Bull 30:165-169.
8. APA (American Psychiatric Association) Task Force on Electroconvuisive Therapy (1990) The Practice of Electroconvulsive Therapy. Washington, DC: APA Press.
9. Barr LC, Goodman WK, Price LH (1994) Physical symptoms associated with paroxetine discontinuation (Letter). Am J Psychiatry 151:289.
10. Beck AT, Rush AJ, Shaw BF, Emery G (1979) Cognitive Therapy of Depression. New York: Guilford Press.
11. Berlin CS (1996) Fluoxetine withdrawal symptoms. J Clin Psychiatry 57:93-94.
12. Bhuamik S, Wildgust HJ (1996) Treatment outcomes including withdrawal phenomena with fluoxetine and paroxetine in patients with learning disabilities suffering from affective disorders. Hum Psychopharmacol 11:337-338.
13. Bjork K (1983) The efficacy of zimelidine in preventing depressive episodes in recurrent major depressive disorders - a double-blind placebo-controlled study. Acta Psychiatr Scand 68:182-189.
14. Bloch M, Stager SV, Braun AR (1995) Severe psychiatric symptoms associated with paroxetine withdrawal (Letter). Lancet 346:57.
15. Blomgren SL, Krebs W, Wilson M, Ascroft R, Fave M, Rosenbauin J (1997) SSRI dose interruption study: Interim data (Abstract NR 188). In New Research Program & Abstracts, APA 1997 Annual Meeting, p 118.
16. Choo V (1993) Paroxetine and extrapyramidal reactions. Lancet 341:624.
17. Claghorn JL, Feighner JP (1993) A double blind comparison of paroxetine with imipramine in the long-term treatment of depression. J Clin Psychopharmacol 13:23S-27S.
18. Cooper GL (1988) The safety of fluoxetine - an update. Br J Psychiatry 153:77-86.
19. Coppen A, Ghose K, Montgomery S, Rao V, Bailey J Jorgensen A (1978) Continuation therapy with amitriptyline in depression. Br J Psychiatry 133:28-33.
20. Coapland NJ, Bell CJ, Potokar JP (1996) Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 16:350-362.
21. Covi L, Lipman RS, Derogatis LR, Smith JE III, Pattison JH (1974) Drugs and group psychotherapy in neurotic depression. Am J Psychiatry 131:191-198.
22. Debattista C, Schatzberg AF (1995) Physical symptoms associated with paroxetine withdrawal (Letter). Am J Psychiatry 152:1235-1236.
23. Dilsiver SC (1994) Withdrawal phenomena associated with antidepressant and antipsychotic agents. Drug Saf 10:103-114.
24. Dilsaver SC, Greden JF (1984) Antidepressant withdrawal phenomena. Biol Psychiatry 19:237-256.
25. Dilsaver SC, Kronfol Z, Sackellares JC, Greden JF (1983) Antidepressant withdrawal syndromes: Evidence supporting the cholinergic overdrive hypothesis. J Clin Psychopharmacol 3:157-164.
26. Dominguez RA, Goodnick PJ (1995) Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy 15:778-780.
27. Doogan DP, Caillard V (1992) Sertraline in the prevention of depression. Br J Psychiatry 160:217-222.
28. Einbinder E (1995) Fluoxetine withdrawal? (Letter) Am J Psychiatry 132:1235.
29. Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PA, Leber WR, Docherty JP, Fiester SJ, Parloff MB (1989) National Institute of Mental Health Treatment of Depression Collaborative Research Program: General effectiveness of treatments. Arch Gen Psychiatry 46:971-982.
30. Ellison JM (1994) SSRI withdrawal buzz (Letter). J Clin Psychiatry 55:544-545.
31. Entsuah AR, Rudolph RL, Hackett D, Miska S (1996) Efficacy of venlafaxine and placebo during long-term treatment of depression: A pooled analysis of relapse rates. Int Clin Psychopharmacol 11:137-145.
32. Farah A, Lauer TE (1996) Possible venlafaxine withdrawal syndrome. Am J Psychiatry 152-810.
33. Fava GA (1995) Holding on: Depression, sensitization by antidepressant drugs, and the prodigal experts. Psychother Psychosom 64:57-61.
34. Fava GA, Grandi S (1995) Withdrawal syndromes after paroxetine and sertraline discontinuation. J Clin Psychopharmacol 15:374-375.
35. Feiger AD, Bielski RD, Bremmer D, Heiser J, Trivedi M, Wilcox CS (1996) Efficacy of nefazodone in continuation treatment of depression. Psychopharmacol Bull 32:444.
36. Feiger AD, Bielski RD, Heiser J, Trivedi M (1997) Efficacy of nefazodone in continuation treatment of depression (Abstract 99-7). Biol Psychiatry 42:279S.
37. Frank E (1997) Enhancing patient outcomes: Treatment adherence. J Clin Psychiatry 58:11-14.
38. Frank E, Kupfer DJ, Perel JM, Comes C, Jarrett DB, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ (1990) Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47:1093-1099.
39. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiatry 48:851-855.
40. Frank E, Kupfer DJ, Perel JM, Comes C, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ (1993) Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord 27:139-145.
41. Frost L, Lal S (1995) Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors (Letter). Am J Psychiatry 152:810.
42. Georgotis A, McCue RE, Cooper TB (1989) A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 46:783-786.
43. Giakas WJ, Davis JM (1997) Intractable withdrawal from venlafaxine treated with fluoxetine. Psychiatric Ann 27:85-92.
44. Glen AIM, Johnson AL, Shepherd M (1984) Continuation therapy with lithium and amitriptyline in unipolar depressive illness: A randomized double-blind controlled trial. Psychol Med 14:37-50.
45. Goldberg JF, Sacks MH, Kocsis JH (1995) Attenuation of response to serotonin reuptake inhibitors (Letter). Am J Psychiatry 152:154.
46. Goodwin FK, Jamison KR (1990) Course and outcome. In: Manic-Depressive Illness. New York: Oxford University Press, pp 127-156.
47. Greden JF (1993) Antidepressant maintenance medications: When to discontinue and how to stop. J Clin Psychiatry 54:39-45.
48. Greden JF (in press) Antidepressant maintenance medications. In Halbreich U, Montgomery S (eds). Pharmacotherapy of Mood and Cognition. Washington, DC: APA Press.
49. Greden JF, Gardner R, King LD, Grunhaus L, Carroll BJ, Kronfol Z (1983) Dexamethasone suppression tests in antidepressant treatment of melancholia: The process of normalization and testretest reproducibility. Arch Gen Psychiatry 40:493-500.
50. Grof P, Angst J, Haines T (1973) The clinical course of depression: Practical issues. In Angst J, Stuttgart J (eds): Classification and Prediction of Outcome of Depression. New York: FK Schattauer Verlag.
51. Hirschfeld RMA (1994) Guidelines for the long-term treatment of depression. J Clin Psychiatry 55:61-69.
52. Hirschfeld RMA, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F, Endicott J, Froom J, Goldstein M, Gorman JM, Guthrie D, Marck RG, Maurer TA, Meyer R, Phillips K, Ross J, Schwenk TL, Sharfstein SS, Thase ME, Wyatt RJ (1997) The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 277:333-340.
53. Hotopf M, Hardy R, Lewis G (1997) Discontinuation rates of SSRIs and tricyclic antidepressants: A meta-analysis and investigation of heterogeneity. Br J Psychiatry 170:120-127.
54. Inman W, Kubota K, Pearce G, Wilton L (1993) PEM report number 6 paroxetine. Pharmacoepidemiology and drug safety 2:393-422.
55. Jacobs BL, Fornal CA (1993) 5HT and motor control: A hypothesis. Trends Neurosci 16:346-352.
56. Jacobson NS, Dobson K, Fruzzetti AE, Schmaling KB, Salusky S (1991) Marital therapy as a treatment for depression. J Consult Clin Psychol 59.547-557.
57. Jakovljevic M, Mewett S (1991) Comparison between paroxetine, imipramine and placebo in preventing recurrent major depressive episodes. Eur Neuropsychopharmacol 1:440.
58. Judd LL (1997) A prospective study of subsyndromal and syndromal symptomatology in patients with unipolar major depressive episodes (Abstract 81-5). Biol Psychiatry 42:221S-222S.
59. Kane JM, Quitkin FM, Rifkin A, Ramos-Lorenzo JR, Nayak DD, Howard A (1982) Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness. A prospective placebo-controlled comparison. Arch Gen Psychiatry 39:1065-1069.
60. Kasantikul D (1995) Reversible delirium after discontinuation of fluoxetine. J Med Assoc Thai 78:53-54.
61. Katon W, Von Korff M, Lin E, Bush T, Ormel J (1992) Adequacy and duration of antidepressant treatment in primary care. Med Care 30:67-76.
62. Keller MB (1985) Chronic and recurrent affective disorders: Incidence, course, and influencing factors. In Keinali D, Racagni G (eds): Chronic Treatments in Neuropsychiatry. New York: Raven Press.
63. Keller MB (1988) Diagnostic issues and clinical course of unipolar illness. In Francis AJ, Hales RE (eds): Review of Psychiatry, Vol. 7. Washington DC: APA Press, pp 188-212.
64. Keller MB, Shapiro RW, Lavori PW, Wolfe N (1982a) Recovery in major depressive disorder: Analysis with the life table and regression models. Arch Gen Psychiatry 39:905-910.
65. Keller MB, Shapiro RW, Lavori PW, Wolfe N (1982b) Relapse in major depressive disorder: Analysis with the life table. Arch Gen Psychiatry 39:911-915.
66. Keller MB, Lavori PW, Kierman GL (1983) Predictors of relapse in major depressive disorder. JAMA 250:3299-3304.
67. Keuthen NJ, Cyr P, Ricciardi JA, Minichiello WE, Buttolph ML, Jeruke MA (1994) Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmacol 14:206-207.
68. Klerman GL, DiMascio A, Weissman MM, Prusoff B, Paykel EF (1974) Treatment of depression by drugs and psychotherapy. Am J Psychiatry 131:186-191.
69. Koopowitz LF, Berk M (1995) Paroxetine induced withdrawal effects. Hum Psychopharmacol 10:147-148.
70. Kocsis JH, Schatzberg AF, Rush AJ, Korstein S, Klein D, Hirschfeld RMA (1997) Maintenance therapy of chronic depression: A placebo-controlled trial of sertraline (Abstract 90-28). Biol Psychiatry 42:240S.
71. Koran L, DeBattista C, Gelenberg A, Hirschfeld R, Keitner G, Keller MB, Klein D, Kocsis JH, Komstein S, Schatzberg A, Thase M (1996) Sertraline or imipramine for chronic depression: 7-month results. Psychopharmacol Bull 32:396.
72. Kraepelin E (1921) Manic-depressive Illness. Edinburgh: E&S Livingstone.
73. Kuhn R (1957) On the treatment of depressive states with an iminodibenzyl derivative (G22355). Schweiz Med Wochenschr 87:1135.
74. Kupfer DJ (1991) Long-term treatment of depression. J Clin Psy-chiatry 52:28-34.
75. Kupfer DJ, Frank E, Perel JM, Comes C, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ (1992) Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 49:769-773.
76. Landry P, Roy L (1997) Withdrawal hypomania associated with paroxetine. J Clin Psychopharmacol 17:60-61.
77. Lauterbach EC (1994) Fiuoxetine withdrawal and thalamic pain. Neurology 44:983-984.
78. Leiter FL, Nierenberg AA, Sanders KM, Stem TA (1995) Discontinuation reactions following sertraline. Biol Psychiatry 38:694-695.
79. Louie AK, Lannon RA, Ajari LJ (1994) Withdrawal reaction after sertraline discontinuation. Am J Psychiatry 151:450.
80. Louie AK, Lannon RA, Kirsch MA, Lewis TB (1996) Venlafaxme withdrawal reactions. Am J Psychiatry 153:1652.
81. Mann AM, MacPherson A (1959) Clinical experience with imipramine (G22355) in the treatment of depression. Can Psychiat Assoc J 4:38-47.
82. Mendels J (1992) The acute and long-term treatment of major depression. Int Clin Psychopharmacol 7:21-29.
83. Montgomery SA (1994) Long-term treatment of depression. Br J Psychiatry 165:31-36.
84. Montgomery SA (1997) Dosage of antidepressants and long-term treatment of depression (Abstract 70-4). Biol Psychiatry 42:202S.
85. Montgomery SA, Dunbar G (1993) Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 8:189-195.
86. Montgomery SA, Kremer ME (1997) Mirtazapine vs amitriptyline in relapse prevention: A placebo controlled study (Abstract 90-71). Biol Psychiatry 42:248S.
87. Montgomery SA, Dufour H, Brion S, Gailledreau J, Laqueille X, Ferrey G, Moron P, Parant-Lucena N, Singer L, Danion JM, Beuzen JN, Pierredon MA (1988) The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 153:69-76.
88. Montgomery SA, Montgomery DB, Green M (1991) The efficacy of prophylactic treatment with 5-HT reuptake inhibitors. In Racagni G, Brunello N, Fukuda T (eds): Biological Psychiatry, Vol. 1, pp 67-68. Excerpta Medica, New York.
89. Montgomery SA, Rasmussen JGC, Tanghoj P (1993) A 24 week study of 20 mg citalopram, 40 mg citalopram and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 9:181-188.
90. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, Clare A, Nutt D (1994) Selective serotonin reuptake inhibitors: Meta-analysis of discontinuation rates. Int Clin Psychopharmacol 9:47-53.
91. Mueller TI (1997) Ten-year cumulative probability of recurrence after recovery from an index episode of MDD (Abstract NR 197). In New Research Program & Abstracts, APA 1997 Annual Meeting, p 121.
92. Nemeroff CB (1994) Evolutionary trends in the pharmacotherapeutic management of depression. J Clin Psychiatry 55:3-15.
93. NIMH/NIIH Consensus Development Panel (1985) Mood disorders: Pharmacologic prevention of recurrences. NIMH/NIH Consensus Development Conference Statement. Am J Psych 42:469-476.
94. Otani K, Tanaka O, Kaneko S, Ishida M, Yasui N, Fukushima Y (1994) Mechanisms of the development of trazodone withdrawal symptoms. Int Clin Psychopharmacol 9:131-133.
95. Pacheco L, Malo P, Aragues E, Etxebeste M (1996) More cases of paroxetine withdrawal syndrome. Br J Psychiatry 169:384.
96. Phillips SD (1995) A possible paroxetine withdrawal syndrome (Letter). AmJ Psychiatry 152:645-646.
97. Post RM, Rubinow DR, Ballenger JC (1986) Conditioning and sensitization in the longitudinal course of affective illness. Br J Psychiatry 149:191-201.
98. Post RM (1992) Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 149:999-1010.
99. Post RM (1994) Mechanisms underlying the evolution of affective disorders: Implications for long-term treatment. In Grunhaus L, Greden JF (eds): Progress in Psychiatry: Severe Depressive Disorders. Washington, DC: APA Press, pp 23-65.
100. Preskorn SH (1995) Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 56:12-21.
101. Price JS, Waller PC, Wood SM, MacKay AV (1996) A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 42:757-763.
102. Prien RF, Klett J, Caffey EM (1973) Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study. Arch Gen Psychiatry 29:420-425.
103. Prien RF, Kupfer DJ, Mansky PA, Small JG, Tuason VB, Voss CB, Johnson WE (1984) Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NLMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 41:1096-1104.
104. Pyke RE (1995) Paroxetine withdrawal syndrome (Letter). Am J Psychiatry 152:149-150.
105. Reeves RR, Pinkofsky HB (1996) Lhermitte's sigh in paroxetine withdrawal. J Clin Psychopharmacol 16:411-412.
106. Rehm LP (1979) Behavior Therapy for Depression. New York: Academic Press.
107. Ribeiro SCM, Grunhaus L, Tandon R, Greden JF (1993) The DST as a predictor of outcome in depression: A meta-analysis. Am J Psychiatry 150:1618-1629.
108. Rohinson DS, Lerfald SC, Bennett B, Laux D, Devereaux E, Kayser A, Corcella J, Albright D (1991) Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: A double-blind placebo-controlled discontinuation study. Psychopharmacol Bull 27.31-39.
109. Rosenstock HA (1996) Sertraline withdrawal in two brothers: A case report. Int Clin Psychopharmacol 11:58-59.
110. Rouillon F, Serrurier D, Miller H, Gerard M (1991) Prophylactic efficacy of inaprotoline on unipolar depression relapse. J Clin Psychiatry 52:423-431.
111. Roy-Byme P, Post RM, Uhde TW, Porcu T, Davis D (1985) The longitudinal course of recurrent affective illness: Life chart data from research patients at the NIMH. Acta Psychiatr Scand 317:1-34.
112. Rush AJ, Beck AT, Kovacs M, Hollon SD (1977) Comparative efficacy of cognitive therapy and pharmacotherapy in the treatments of depressed outpatients. Cogn Ther Res 1:17-37.
113. Schatzberg AF (1997) Treatment of severe depression with the selective serotonin reuptake inhibitors. Depress Anxiety 4:182-189.
114. Schou M (1979) Lithium as a prophylactic agent in unipolar affective illness. Arch Gen Psychiatry 36:849-851.
115. Silverstone T (1992) New aspects in the treatment of depression. Int Clin Psychopharmacol 5:4144.
116. Stoukides JA, Stoukides CA (1991) Extrapyramidal symptoms upon discontinuation of fluoxetine. Am J Psychiatry 148:1263.
117. Szabadi E (1992) Fluvoxamine withdrawal syndrome. Br J Psychiatry 160:283-284.
118. Thase ME (1990) Relapse and recurrence in unipolar major depression: Short-term and long-term approaches. J Clin Psychiatry 51:51-59.
119. Tollefson GD (1993) Adverse drug reactions/interactions in maintenance therapy. J Clin Psychiatry 54:48-58.
120. Wilson K, Berti C, Whitehead A (1997) The efficacy of sertraline in elderly patients suffering from major depression (Abstract 90-41). Biol Psychiatry 42:2425.
121. Zis AP, Goodwin FK (1979) Major affective disorders as a recurrent illness: A critical review. Arch Gen Psychiatry 36:835-839.